Cardiotoxicity in breast cancer patients treated with chemoradiotherapy

Abstract

With national breast cancer screening programs leading to earlier diagnosis and improved treatments, more women are achieving long-term remission. However, this has resulted in rising rates of cardiotoxicity in breast cancer survivors consequent to their cancer therapies. Anthracyclines, a cornerstone treatment in breast cancer, carry a significant risk of short- and long-term cardiotoxicity through inhibition of topoisomerase II, preventing DNA repair and increasing oxidative stress. This most commonly manifests in the form of left ventricular (LV) systolic dysfunction or heart failure, and in severe cases, death. Many of the other treatments, including taxanes, cyclophosphamide, human epidermal growth factor receptor 2 inhibitors, immunotherapies, hormone therapies, and radiotherapy, also carry a risk of cardiac injury in the form of heart failure, arrhythmias, myocarditis, and pericardial disease. Surveillance has traditionally been performed by monitoring LV ejection fraction by transthoracic echocardiography. However, this has been found to be a late marker of cardiotoxicity, with damage potentially irreversible, and may reflect a missed opportunity for early intervention. Research has focused on identifying cardiac biomarkers and advanced imaging techniques, including strain analysis, to detect subclinical myocardial injury or dysfunction prior to irreversible damage, with LV global longitudinal strain a sensitive marker of subclinical LV systolic dysfunction and superior predictor of future cardiovascular events. Further research is needed to establish standardized guidelines on surveillance and management of this vulnerable patient cohort.

Keywords

breast cancer / anthracyclines / cardio-oncology / strain

References

[1] Menon G, Alkabban FM, Ferguson T. Breast Cancer. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2026.

[2] Freihat O, Sipos D, Kovacs A. Global burden and projections of breast cancer incidence and mortality to 2050: a comprehensive analysis of GLOBOCAN data. Front Public Health. 2025; 13: 1622954.

[3] Arzanova E, Mayrovitz HN. The Epidemiology of Breast Cancer. In: Mayrovitz HN, editor. Breast Cancer [Internet]. Brisbane (AU): Exon Publications; 2022.

[4] Kaklamani VG, Arteaga CL. Breast cancer: The good, the bad, and an important call to effective risk reduction strategies. CA: Cancer J Clin. 2024; 74: 471-4.

[5] Tang DD, Ye ZJ, Liu WW, Wu J, Tan JY, Zhang Y, et al. Survival feature and trend of female breast cancer: A comprehensive review of survival analysis from cancer registration data. Breast. 2025; 79: 103862.

[6] Bostany GS, Chen Y, Francisco L, Dai C, Meng Q, Sparks JR, et al. Cardiac dysfunction (CD) among breast cancer survivors (BCS): Role of cardiotoxic therapy and cardiovascular risk factors. J Clin Oncol. 2023; 41: 12078.

[7] Bardia A, Arieas ET, Zhang Z, Defilippis A, Tarpinian K, Jeter S, et al. Comparison of breast cancer recurrence risk and cardiovascular disease incidence risk among postmenopausal women with breast cancer. Breast Cancer Res Treat. 2011; 131: 907-14.

[8] Czajka ML, Pfeifer C. Breast Cancer Surgery. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2026.

[9] Teven CM, Schmid DB, Sisco M, Ward J, Howard MA. Systemic Therapy for Early-Stage Breast Cancer: What the Plastic Surgeon Should Know. Eplasty. 2017; 17: e7.

[10] Shah AN, Gradishar WJ. Adjuvant Anthracyclines in Breast Cancer: What Is Their Role? Oncologist. 2018; 23: 1153-61.

[11] Vuger AT, Tiscoski K, Apolinario T, Cardoso F. Anthracyclines in the treatment of early breast cancer friend or foe? Breast. 2022; 65: 67-76.

[12] Douedi S, Carson MP. Anthracycline Medications (Doxorubicin). In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2026.

[13] Venkatesh P, Kasi A. Anthracyclines. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023.

[14] Ismail U, Killeen RB. Taxane Toxicity. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2026.

[15] Maloney SM, Spring CA, Morejon-Lasso LV, Prosperi JR. Mechanisms of Taxane Resistance. Cancers. 2020; 12: 3323.

[16] Giffoni de Mello Morais Mata D, Rush MB, Smith-Uffen M, Younus J, Lohmann AE, Trudeau M, et al. The Omission of Anthracycline Chemotherapy in Women with Early HER2-Negative Breast Cancer-A Systematic Review and Meta-Analysis. Curr Oncol. 2024; 31: 4486-506.

[17] Falzone L, Salomone S, Libra M. Evolution of Cancer Pharmacological Treatments at the Turn of the Third Millennium. Front Pharmacol. 2018; 9: 1300.

[18] Ogino MH, Tadi P. Cyclophosphamide. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2026.

[19] Burkard ME, Wisinski KB, Njiaju UO, Donohue S, Hegeman R, Stella A, et al. Feasibility of 4 Cycles of Docetaxel and Cyclophosphamide Every 14 Days as an Adjuvant Regimen for Breast Cancer: A Wisconsin Oncology Network Study. Clin Breast Cancer. 2014; 14: 205-11.

[20] Xia X, Gong C, Zhang Y, Xiong H. The History and Development of HER2 Inhibitors. Pharmaceuticals. 2023; 16: 1450.

[21] Patel A, Unni N, Peng Y. The Changing Paradigm for the Treatment of HER2-Positive Breast Cancer. Cancers. 2020; 12: 2081.

[22] Trayes KP, Cokenakes SEH. Breast Cancer Treatment. Am Fam Physician. 2021; 104: 171-8.

[23] Xu Y, Zhang B, Wu H, Wu Y. Current Status of Breast Cancer Immunotherapy and Prognosis-Related Markers. Breast Cancer: Targets Ther. 2025; 17: 339-48.

[24] Dvir K, Giordano S, Leone JP. Immunotherapy in Breast Cancer. Int J Mol Sci. 2024; 25: 7517.

[25] Marth C. Endocrine Therapy-What Else? Breast Care. 2008; 3: 301-2.

[26] Lumachi F, Santeufemia DA, Basso SM. Current medical treatment of estrogen receptor-positive breast cancer. World J Biol Chem. 2015; 6: 231-9.

[27] Patel P, Jacobs TF. Tamoxifen. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2026.

[28] Fong MK, Patel P. Aromatase Inhibitors. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2026.

[29] Jaffray DA, Gospodarowicz MK. Radiation Therapy for Cancer. In: Gelband H, Jha P, Sankaranarayanan R, Horton S, editors. Cancer: Disease Control Priorities. 3rd ed. Washington (DC): The International Bank for Reconstruction and Development/The World Bank; 2015.

[30] Kim CS, Algan O. Radiation Therapy for Early-Stage Breast Cancer. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2026.

[31] Langlands FE, Horgan K, Dodwell DD, Smith L. Breast cancer subtypes: response to radiotherapy and potential radiosensitisation. Br J Radiol. 2014; 86: 20120601.

[32] Emerson P, Stefani L, Boyd A, Richards D, Hui R, Altman M, et al. Alterations in Left Atrial Strain in Breast Cancer Patients Immediately Post Anthracycline Exposure. Heart Lung Circ. 2024; 33: 684-92.

[33] Kundnani NR, Passini V, Stefania Carlogea I, Dumitrescu P, Meche V, Buzas R, et al. Overview of Oncology: Drug-Induced Cardiac Toxicity. Medicina. 2025; 61: 709.

[34] Keramida K, Lopez-Fernandez T, Anker MS, Petrie MC, Ameri P, Anderson LJ, et al. Heart Failure with Preserved Ejection Fraction in Cancer Patients and Survivors. A Scientific Statement of the Heart Failure Association of the ESC and the ESC Council of Cardio-Oncology. Eur J Heart Fail. 2025; 27: 2152-67.

[35] Alkofide H, Alnaim L, Alorf N, Alessa W, Bawazeer G. Cardiotoxicity and Cardiac Monitoring Among Anthracycline-Treated Cancer Patients: A Retrospective Cohort Study. Cancer Manag Res. 2021; 13: 5149-59.

[36] Xie S, Sun Y, Zhao X, Xiao Y, Zhou F, Lin L, et al. An update of the molecular mechanisms underlying anthracycline induced cardiotoxicity. Front Pharmacol. 2024; 15: 1406247.

[37] Johnson J, Mohsin S, Houser SR. Cardiomyocyte Proliferation as a Source of New Myocyte Development in the Adult Heart. Int J Mol Sci. 2021; 22: 7764.

[38] Tran DB, AlAshi AK, Hernandez A. Delayed Onset Anthracycline-Associated Cardiotoxicity Presenting as Acute Decompensated Heart Failure Seven Years After Chemotherapy Completion. Cureus. 2021; 13: e16920.

[39] Johnson M, Keyes D. Anthracycline Toxicity. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2026.

[40] Shil S, Kumar P, Mumbrekar KD. Cancer therapy-induced cardiotoxicity: mechanisms and mitigations. Heart Fail Rev. 2025; 30: 1075-92.

[41] Pamungkas RP, Pratiwi L, Sutanto H. HER2-targeted therapies and cardiotoxicity: From major concern to manageable risk. Curr Probl Cardiol. 2025; 50: 103168.

[42] Rubio-Infante N, Ramírez-Flores YA, Castillo EC, Lozano O, García-Rivas G, Torre-Amione G. Cardiotoxicity associated with immune checkpoint inhibitor therapy: a meta-analysis. Eur J Heart Fail. 2021; 23: 1739-47.

[43] He Y, Zhang J, Shen G, Liu L, Zhao Q, Lu X, et al. Aromatase inhibitors and risk of cardiovascular events in breast cancer patients: a systematic review and meta-analysis. BMC Pharmacol Toxicol. 2019; 20: 62.

[44] Soumarová R, Rušinová L. Cardiotoxicity of breast cancer radiotherapy-overview of current results. Rep Pract Oncol Radiother. 2020; 25: 182-6.

[45] Morelli MB, Bongiovanni C, Da Pra S, Miano C, Sacchi F, Lauriola M, et al. Cardiotoxicity of Anticancer Drugs: Molecular Mechanisms and Strategies for Cardioprotection. Front Cardiovasc Med. 2022; 9: 847012.

[46] Early Breast Cancer Trialists’ Collaborative Group (EBCTCG); Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Anthracycline-containing and taxane-containing chemotherapy for early-stage operable breast cancer: a patient-level meta-analysis of 100 000 women from 86 randomised trials. Lancet. 2023; 401: 1277-92.

[47] Dhesi S, Chu MP, Blevins G, Paterson I, Larratt L, Oudit GY, et al. Cyclophosphamide-Induced Cardiomyopathy. J Investig Med High Impact Case Rep. 2013; 1: 2324709613480346.

[48] Kajanto LA, Gheorghe AS, Komporaly IA, Mihaila RI, Iovanescu EA, Radu AM, et al. Cardiotoxic Effects of HER2-Targeted Therapies: Insights From a Retrospective Study at a Romanian Oncology Center. Cureus. 2025; 17: e83012.

[49] Copeland-Halperin RS, Liu JE, Yu AF. Cardiotoxicity of HER2-targeted therapies. Curr Opin Cardiol. 2019; 34: 451-8.

[50] Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, et al. Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer. N Engl J Med. 2005; 353: 1659-72.

[51] O'Rourke H, Hart C, De Boer RH. Current usage of pembrolizumab in triple negative breast cancer (TNBC). Expert Rev Anticancer Ther. 2024; 24: 253-61.

[52] Xiao L, Liu W, Ji Y, Li Q, Pan J, Xie R. Immunotherapy-related cardiovascular toxicity: from mechanisms to management. Front Pharmacol. 2026; 17: 1762011.

[53] Safi M, Ahmed H, Al-Azab M, Xia YL, Shan X, Al-Radhi M, et al. PD-1/PDL-1 Inhibitors and Cardiotoxicity; Molecular, Etiological and Management Outlines. J Adv Res. 2021; 29: 45-54.

[54] Zhou F, Liu G, Zhang S, Luo C, Hu S, Wan S, et al. Cardiotoxicity in cancer immunotherapy: a systematic review and global meta-analysis. J Transl Med. 2025; 23: 718.

[55] Boszkiewicz K, Piwowar A, Petryszyn P. Aromatase Inhibitors and Risk of Metabolic and Cardiovascular Adverse Effects in Breast Cancer Patients-A Systematic Review and Meta-Analysis. J Clin Med. 2022; 11: 3133.

[56] Pavone ME, Bulun SE. The Use of Aromatase Inhibitors for Ovulation Induction and Superovulation. J Clin Endocrinol Metab. 2013; 98: 1838-44.

[57] Miller VM, Duckles SP. Vascular Actions of Estrogens: Functional Implications. Pharmacol Rev. 2008; 60: 210-41.

[58] Drost L, Yee C, Lam H, Zhang L, Wronski M, McCann C, et al. A Systematic Review of Heart Dose in Breast Radiotherapy. Clin Breast Cancer. 2018; 18: e819-24.

[59] Mędrek S, Rolek K, Homotnik J, Szmit S. Cardioprotection for radiation-induced heart disease in breast cancer patients. Front Pharmacol. 2026; 16: 1742769.

[60] Yang WC, Chen YH, Wang CC, Lai SF, Lu SH, Ho LT, et al. Evaluation of cardiotoxicity following breast cancer irradiation in an Asian cohort in real-world settings. Breast. 2025; 84: 104581.

[61] Belzile-Dugas E, Eisenberg MD. Radiation-Induced Cardiovascular Disease: Review of an Underrecognized Pathology. J Am Heart Assoc. 2021; 10: e021686.

[62] Zhang X, Sun Y, Zhang Y, Fang F, Liu J, Xia Y, et al. Cardiac Biomarkers for the Detection and Management of Cancer Therapy-Related Cardiovascular Toxicity. J Cardiovasc Dev Dis. 2022; 9: 372.

[63] Sharma S, Jackson PG, Makan J. Cardiac troponins. J Clin Pathol. 2004; 57: 1025-6.

[64] Canty JM Jr. Myocardial injury, troponin release, and cardiomyocyte death in brief ischemia, failure, and ventricular remodeling. Am J Physiol Heart Circ Physiol. 2022; 323: H1-15.

[65] Daniels LB, Maisel AS. Natriuretic Peptides. J Am Coll Cardiol. 2007; 50: 2357-68.

[66] Novack ML, Zubair M. Natriuretic Peptide B Type Test. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2026.

[67] Andreescu M. Recent Advances in Serum Biomarkers for Cardiological Risk Stratification and Insight into the Cardiac Management of the Patients With Hematological Malignancies Treated With Targeted Therapy. Cureus. 2023; 15: e49696.

[68] Ananthan K, Lyon AR. The Role of Biomarkers in Cardio-Oncology. J Cardiovasc Transl Res. 2020; 13: 431-50.

[69] Agha A, Zarifa A, Kim P, Iliescu C, Gladish G, Hassan S, et al. The Role of Cardiovascular Imaging and Serum Biomarkers in Identifying Cardiotoxicity Related to Cancer Therapeutics. Methodist DeBakey Cardiovasc J. 2019; 15: 258-66.

[70] Tian S, Hirshfield KM, Jabbour SK, Toppmeyer D, Haffty BG, Khan AJ, et al. Serum Biomarkers for the Detection of Cardiac Toxicity after Chemotherapy and Radiation Therapy in Breast Cancer Patients. Front Oncol. 2014; 4: 277.

[71] Taub CC, Stainback RF, Abraham T, Forsha D, Garcia-Sayan E, Hill JC, et al. Guidelines for the Standardization of Adult Echocardiography Reporting: Recommendations From the American Society of Echocardiography. J Am Soc Echocardiogr. 2025; 38: 735-74.

[72] Galderisi M, Cosyns B, Edvardsen T, Cardim N, Delgado V, Di Salvo G, et al. Standardization of adult transthoracic echocardiography reporting in agreement with recent chamber quantification, diastolic function, and heart valve disease recommendations: an expert consensus document of the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging. 2017; 18: 1301-10.

[73] Chen M, Lee WH, Lu CH, Chang HC, Tung CC, Siow YY, et al. 2025 Expert Consensus Recommendations for the Diagnostic Requirements in Routine Practices of Transthoracic Echocardiography. Acta Cardiol Sin. 2025; 41: 1-49.

[74] Plana JC, Galderisi M, Barac A, Ewer MS, Ky B, Scherrer-Crosbie M, et al. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging. 2014; 15: 1063-93.

[75] Shams P, Goyal A, Makaryus AN. Left Ventricular Ejection Fraction. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2026.

[76] Emerson P, Deshmukh T, Stefani L, Mahendran S, Hogg M, Brown P, et al. Left atrial strain in cardiac surveillance of bone marrow transplant patients with prior anthracycline exposure. Int J Cardiol. 2022; 354: 68-74.

[77] Potter E, Marwick TH. Assessment of Left Ventricular Function by Echocardiography: The Case for Routinely Adding Global Longitudinal Strain to Ejection Fraction. JACC Cardiovasc Imaging. 2018; 11: 260-74.

[78] Upshaw JN, Finkelman B, Hubbard RA, Smith AM, Narayan HK, Arndt L, et al. Comprehensive Assessment of Changes in Left Ventricular Diastolic Function With Contemporary Breast Cancer Therapy. JACC: Cardiovasc Imaging. 2020; 13: 198-210.

[79] Palazzuoli A, Correale M, Iacoviello M, Gronda E. Does the Measurement of Ejection Fraction Still Make Sense in the HFpEF Framework? What Recent Trials Suggest. J Clin Med. 2023; 12: 693.

[80] Sławiński G, Hawryszko M, Liżewska-Springer A, Nabiałek-Trojanowska I, Lewicka E. Global Longitudinal Strain in Cardio-Oncology: A Review. Cancers. 2023; 15: 986.

[81] Krishnasamy R, Isbel NM, Hawley CM, Pascoe EM, Burrage M, Leano R, et al. Left Ventricular Global Longitudinal Strain (GLS) Is a Superior Predictor of All-Cause and Cardiovascular Mortality When Compared to Ejection Fraction in Advanced Chronic Kidney Disease. PLOS ONE. 2015; 10: e0127044.

[82] Marwick TH. Global Longitudinal Strain Monitoring to Guide Cardioprotective Medications During Anthracycline Treatment. Curr Oncol Rep. 2022; 24: 687-94.

[83] Shaaban NH, Abayazeed RM, Sobhy MA, Elsharkawy EM, Hammad BA. Role of Global Left Ventricle Longitudinal Strain and Cardiac Biomarkers in the Early Detection of Cancer Therapy-Related Dysfunction in Patients Treated With Cardiotoxic Chemotherapeutic Drugs in a Cardio-Oncology Clinic. Cureus. 2024; 16: e71766.

[84] Stone JR, Kanneganti R, Abbasi M, Akhtari M. Monitoring for Chemotherapy-Related Cardiotoxicity in the Form of Left Ventricular Systolic Dysfunction: A Review of Current Recommendations. JCO Oncol Pract. 2021; 17: 228-36.

[85] Buggey J, Alenezi F, Yoon HJ, Phelan M, DeVore AD, Khouri MG, et al. Left Ventricular Global Longitudinal Strain in Patients with Heart Failure with Preserved Ejection Fraction: Outcomes Following an Acute Heart Failure Hospitalization. ESC Heart Fail. 2017; 4: 432-9.

[86] Cuomo G, Iannone FP, Di Lorenzo A, Testa C, Ciccarelli M, Venturini E, et al. Potential Role of Global Longitudinal Strain in Cardiac and Oncological Patients Undergoing Cardio-Oncology Rehabilitation (CORE). Clin Pract. 2023; 13: 384-97.

[87] Kwan ML, Cheng RK, Iribarren C, Shen H, Laurent CA, Roh JM, et al. Risk of heart failure with preserved versus reduced ejection fraction in women with breast cancer. Breast Cancer Res Treat. 2022; 193: 669-75.

[88] Deshmukh T, Emerson P, Geenty P, Mahendran S, Stefani L, Hogg M, et al. The utility of strain imaging in the cardiac surveillance of bone marrow transplant patients. Heart. 2021; 108: 550-7.

[89] Goyal A, Abbasi HQ, Yakkali S, Khan AM, Tariq MD, Sohail AH, et al. Left Atrial Strain as a Predictor of Early Anthracycline-Induced Chemotherapy-Related Cardiac Dysfunction: A Pilot Systematic Review and Meta-Analysis. J Clin Med. 2024; 13: 3904.

[90] Di Lisi D, Manno G, Madaudo C, Filorizzo C, Intravaia RCM, Galassi AR, et al. Chemotherapy-related cardiac dysfunction: the usefulness of myocardial work indices. Int J Cardiovasc Imaging. 2023; 39: 1845-53.

[91] Burrage MK, Ferreira VM. The use of cardiovascular magnetic resonance as an early non-invasive biomarker for cardiotoxicity in cardio-oncology. Cardiovasc Diagn Ther. 2020; 10: 610-24.

[92] Johnson JN, Berthod TL, Cai X, Campbell MJ, Dodeja AK, Goode CG, et al. Cardiac magnetic resonance imaging in the assessment of cardiac injury and toxicity from cancer-related chemotherapy. Pediatr Radiol. 2025; 55: 2381-99.